Prostate cancer may progress silently for a long time and is often suspected through PSA changes, examination findings or MRI results. At ReSurgeClinic in Kyrenia / Cyprus, the aim is not to create fear from every PSA rise, but to evaluate risk correctly, plan MRI or biopsy when needed and choose the right follow-up or treatment path for the individual patient.
The main complaint, duration of symptoms, previous treatments, accompanying diseases, medications, expectations and relevant examination findings are evaluated together.
The aim is not to apply the same treatment to every patient, but to understand the underlying mechanism and choose the safest suitable step.
Follow-up, medical treatment, minimally invasive procedures or surgery are discussed step by step according to the patient’s condition.
Prostate cancer may not cause symptoms in the early period. PSA elevation, abnormal examination, family history or suspicious MRI findings can raise suspicion.
A single PSA value is not enough by itself; age, prostate size, previous PSA values and risk factors should be considered.
PSA can be affected by BPH, infection or procedures, but persistent elevation or concerning trend requires structured evaluation.
Multiparametric prostate MRI helps identify suspicious areas and supports the biopsy decision in selected patients.
When risk remains significant after PSA, examination and MRI assessment, prostate biopsy may be recommended. MRI fusion biopsy allows targeted sampling of suspicious areas when appropriate.
The aim is to avoid unnecessary biopsy while not delaying diagnosis in patients who need it.
If cancer is diagnosed, grade, extent, PSA, MRI and patient characteristics are evaluated together.
Active surveillance, surgery, radiotherapy or other treatments are discussed according to the risk group and patient expectations.
Risk is assessed using PSA trend, examination and patient-specific factors.
MRI helps identify suspicious lesions and plan targeted biopsy if needed.
Targeted sampling may increase diagnostic clarity in selected patients.
Follow-up or treatment is planned according to pathology and risk group.
No. PSA can rise for many reasons, but persistent or unexplained elevation needs evaluation.
MRI is helpful, but tissue diagnosis may be required for definitive diagnosis.
No. Some low-risk cancers may be followed with active surveillance; the decision depends on risk.
